Ketazolam and diazepam in anxiety: a controlled study

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Anxiety disorders represent a significant global health burden.
• Pharmacological interventions are a cornerstone of anxiety treatment.
• Benzodiazepines are commonly prescribed for anxiety, necessitating comparative efficacy studies.

Purpose of the Study:

• To compare the efficacy of ketazolam versus diazepam in treating anxious symptomatology.
• To evaluate the effectiveness of once-daily versus three-times-daily dosing of ketazolam.
• To assess the superiority of ketazolam and diazepam over placebo.

Main Methods:

• A clinical trial involving 222 anxious, non-psychotic outpatients.
• Comparison of ketazolam (once-daily and three-times-daily) with diazepam and placebo.
• Assessment of anxiety symptoms using the Hamilton Anxiety Scale, Covi Anxiety Scale, and physician global improvement ratings.

Main Results:

• Ketazolam demonstrated equal effectiveness in both once-daily and three-times-daily dosing regimens.
• Ketazolam exhibited similar efficacy to diazepam in alleviating anxiety symptoms.
• Both ketazolam and diazepam were significantly more effective than placebo (P < 0.05).
• Symptomatic improvement was observed early in the treatment period.

Conclusions:

• Ketazolam is an effective anxiolytic agent, comparable in efficacy to diazepam.
• Flexible dosing of ketazolam (once-daily or TID) is viable for anxiety symptom relief.
• Ketazolam offers a valuable therapeutic option for non-psychotic anxious outpatients.